CRISPR-Cas9-mediated TCRα/β and B2M knockout to generate “off-the-shelf” allogeneic CAR T cells is also evaluated in other clinical trials for CD19+ leukemia and lymphoma patients (NCT04035434), multiple myeloma patients (NCT04244656) and renal cell carcinoma patients (NCT04438083) (Table 1). This evidence concerns the gene B2M and leukemia.